Growth Demand in Global Migraine Drugs Market with Regional Forecast Till 2025
Posted by Kavita on September 14th, 2019
Bharat Book Bureau Provides the Trending Market Research Report on “Global Migraine Drugs Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024”under Healthcare Category. The report provides information on industry overview, market size, latest developments, industry trends, Key Manufacturers,global presence, device to communicate and their future prospects.
Migraine Drugs Market is a complex debilitating neurological disorder which is often characterized by recurrent severe headaches in one side of the head. It is generally preceded by sensory warning signs and other symptoms such as sensitivity to light and noise, nausea, vomiting, dizziness, etc. It is one of the most common neurological disorders affecting more than 303 million people in the US alone. Even though the disease leads to huge economic burden, yet migraine remains under-recognized and under-treated. Depending upon the frequency and severity of headaches, there are various treatment options ranging from conventional medicines to supplements.
Request a free sample copy of Migraine Drugs Market Report @
Conventional medicine for migraine treatment can be broadly divided into three categories – Abortive, Preventive and Complementary. Some of the common migraine drug classes include Triptan, Calcitonin Gene Related Peptide (CGRP), Tezampanel, Acetylcholine Inhibitors/ Neurotoxins and Ergots Alkaloids. Migraine treatmnet paradigm is dominated by Triptan drug classes.
Global migraine therapeutics market has been relatively stagnant over past several years. Growth of the market is attributed to prevalence of migraine and rising female population, as migraine is said to be one of the most common disorders affecting women. Moreover, other growth contributors of the market are patent expirations of leading drugs and stressed lifestyle. However, certain factors that are restraining growth of the market includes poor efficacy of drugs, regulatory hurdles, low diagnosis rate of migraine and preference for alternative therapies.
The report “Global Migraine Therapeutics Market [By Drug Classes – Triptan, CGRP, Acetylcholine Inhibitors/Neurotoxins, Others; By Region – North America (The US), Europe (The UK, Germany, France, Italy & Spain) and Asia Pacific (Japan) – Outlook 2025”provides information on the current scenario, detailed market outlook of the global migraine therapeutics market with detailed analysis of major drug classes such as Triptan, CGRP, Acetylcholine Inhibitors/ Neurotoxins and other drug classes. The market is further analysed with detailed market outlook for global as well as regional markets such as North America, Europe and Asia Pacific. The analysis is provided for G7 nations. Future forecasts of Migraine treatment market overall and across various sub-segments has been provided till 2025, for all the geographies and all the drug classes. Furthermore, major industry players have been prudently analysed in the competitive landscape section of the report in order to provide key comparative insights.
Major industry players operating in the global migraine therapeutics market includes Eli Lilly & Company, Teva Pharmaceutical Industries, Alder Biopharmaceuticals, Amgen Inc., AbbVie Inc., Pfizer Inc., among others. These players are profiled herein based on attributes such as business overview, product segments and financial analysis. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global as well as regional migraine market.
Browse our full report with Table of Contents:
About Bharat Book Bureau:
Like it? Share it!
About the AuthorKavita
Joined: June 10th, 2019
Articles Posted: 320
More by this author